Related Experiment Video
Updated: Oct 25, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development
Passley Hargrove-Grimes1, Lucie A Low2, Danilo A Tagle2
1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA, passley.hargrove@nih.gov.
None:
Microphysiological systems (MPS) or tissue chips/organs-on-chips are novel in vitro models that emulate human physiology at the most basic functional level. In this review, we discuss various hurdles to widespread adoption of MPS technology focusing on issues from multiple stakeholder sectors, e.g., academic MPS developers, commercial suppliers of platforms, the pharmaceutical and biotechnology industries, and regulatory organizations. Broad adoption of MPS technology has thus far been limited by a gap in translation between platform developers, end-users, regulatory agencies, and the pharmaceutical industry. In this brief review, we offer a perspective on the existing barriers and how end-users may help surmount these obstacles to achieve broader adoption of MPS technology.
More Related Videos
11:06Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
Related Concept Videos
Preclinical Development: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
In Vitro Drug Release Testing: Overview, Development and Validation
Measurement of Bioavailability: Pharmacodynamic Methods